Diffusion Pharmaceuticals LLC Closes $5 Million Financing; Completes Enrollment and Dosing in Phase 2 Trial In Brain Cancer

CHARLOTTESVILLE, VAJune 20, 2013 – Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments for major unmet medical needs, today announced that it has closed a $5 million private financing.  This funding round is an addition to the $5 million financing announced in September, 2012, and consists of convertible notes issued primarily to existing investors.  Proceeds will support the Company’s ongoing Phase 2 clinical trial for its lead drug, trans sodium crocetinate (TSC).  Enrollment is closed and TSC dosing is complete in all 59 patients who have newly diagnosed primary brain cancer (glioblastoma multiforme or GBM).  The trial, conducted at 18 major cancer centers around the country, is evaluating the effect on patient safety and survival when TSC is added to the standard-of-care for GBM (i.e., radiation and chemotherapy).

“We’re fortunate to have a high level of interest from patients and clinicians that has allowed us to meet our enrollment goals so quickly,” said David G. Kalergis, Chief Executive Officer.  “The study’s primary endpoints are tumor response and patient survival, and we are looking forward to reaching the one-year survival milestone in the second quarter of 2014.”

Dr. James Larner and Dr. Jason Sheehan of the University of Virginia Medical Center are Study Co-Chairs.  Further information about the trial, which has met enrollment and can no longer accept new patients, may be viewed online at http://clinicaltrials.gov/ct2/show/NCT01465347?term=tsc&rank=4 .